-
2
-
-
84883739977
-
Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma
-
IARC Press, Lyon, C.D. Fletcher, J.A. Bridge, P.C. Hogendoorn (Eds.)
-
Hogendoorn P.C., Bovée J.V., Nielsen G.P. Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone 2013, 264-268. IARC Press, Lyon. 4th edition. C.D. Fletcher, J.A. Bridge, P.C. Hogendoorn (Eds.).
-
(2013)
World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone
, pp. 264-268
-
-
Hogendoorn, P.C.1
Bovée, J.V.2
Nielsen, G.P.3
-
3
-
-
43549101708
-
The clinical approach towards chondrosarcoma
-
Gelderblom H., Hogendoorn P.C., Dijkstra S.D., et al. The clinical approach towards chondrosarcoma. Oncologist 2008, 13(3):320-329.
-
(2008)
Oncologist
, vol.13
, Issue.3
, pp. 320-329
-
-
Gelderblom, H.1
Hogendoorn, P.C.2
Dijkstra, S.D.3
-
4
-
-
79955086282
-
Using epidemiology and genomics to understand osteosarcoma etiology
-
Savage S.A., Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011, 2011:548151.
-
(2011)
Sarcoma
, vol.2011
, pp. 548151
-
-
Savage, S.A.1
Mirabello, L.2
-
5
-
-
45149133744
-
Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
-
Bielack S., Carrle D., Jost L. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl 2):ii94-ii96.
-
(2008)
Ann Oncol
, vol.19
, Issue.SUPPL 2
-
-
Bielack, S.1
Carrle, D.2
Jost, L.3
-
6
-
-
34249999670
-
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma
-
Ferrari S., Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007, 19(4):341-346.
-
(2007)
Curr Opin Oncol
, vol.19
, Issue.4
, pp. 341-346
-
-
Ferrari, S.1
Palmerini, E.2
-
7
-
-
80054914908
-
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
-
Anninga J.K., Gelderblom H., Fiocco M., et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?. Eur J Cancer 2011, 47(16):2431-2445.
-
(2011)
Eur J Cancer
, vol.47
, Issue.16
, pp. 2431-2445
-
-
Anninga, J.K.1
Gelderblom, H.2
Fiocco, M.3
-
8
-
-
20044389664
-
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)
-
Kempf-Bielack B., Bielack S.S., Jurgens H., et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). JClin Oncol 2005, 23(3):559-568.
-
(2005)
JClin Oncol
, vol.23
, Issue.3
, pp. 559-568
-
-
Kempf-Bielack, B.1
Bielack, S.S.2
Jurgens, H.3
-
9
-
-
36049026825
-
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol
-
Serra M., Pasello M., Manara M.C., et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol 2006, 29(6):1459-1468.
-
(2006)
Int J Oncol
, vol.29
, Issue.6
, pp. 1459-1468
-
-
Serra, M.1
Pasello, M.2
Manara, M.C.3
-
10
-
-
84859187031
-
Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line
-
Martins-Neves S.R., Lopes A.O., do Carmo A., et al. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer 2012, 12:139.
-
(2012)
BMC Cancer
, vol.12
, pp. 139
-
-
Martins-Neves, S.R.1
Lopes, A.O.2
do Carmo, A.3
-
11
-
-
80053384729
-
Side population cells isolated from human osteosarcoma are enriched with tumor-initiating cells
-
Yang M., Yan M., Zhang R., et al. Side population cells isolated from human osteosarcoma are enriched with tumor-initiating cells. Cancer Sci 2011, 102(10):1774-1781.
-
(2011)
Cancer Sci
, vol.102
, Issue.10
, pp. 1774-1781
-
-
Yang, M.1
Yan, M.2
Zhang, R.3
-
12
-
-
84873816274
-
CD133 expression in osteosarcoma and derivation of CD133(+) cells
-
Li J., Zhong X.Y., Li Z.Y., et al. CD133 expression in osteosarcoma and derivation of CD133(+) cells. Mol Med Rep 2013, 7(2):577-584.
-
(2013)
Mol Med Rep
, vol.7
, Issue.2
, pp. 577-584
-
-
Li, J.1
Zhong, X.Y.2
Li, Z.Y.3
-
13
-
-
84865392209
-
Molecular pathology and its diagnostic use in bone tumors
-
Szuhai K., Cleton-Jansen A.M., Hogendoorn P.C., et al. Molecular pathology and its diagnostic use in bone tumors. Cancer Genet 2012, 205(5):193-204.
-
(2012)
Cancer Genet
, vol.205
, Issue.5
, pp. 193-204
-
-
Szuhai, K.1
Cleton-Jansen, A.M.2
Hogendoorn, P.C.3
-
14
-
-
78650959663
-
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
-
Stephens P.J., Greenman C.D., Fu B., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144(1):27-40.
-
(2011)
Cell
, vol.144
, Issue.1
, pp. 27-40
-
-
Stephens, P.J.1
Greenman, C.D.2
Fu, B.3
-
15
-
-
0141705379
-
The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability
-
Overholtzer M., Rao P.H., Favis R., et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci USA 2003, 100(20):11547-11552.
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, Issue.20
, pp. 11547-11552
-
-
Overholtzer, M.1
Rao, P.H.2
Favis, R.3
-
16
-
-
84859706280
-
At-risk populations for osteosarcoma: the syndromes and beyond
-
Calvert G.T., Randall R.L., Jones K.B., et al. At-risk populations for osteosarcoma: the syndromes and beyond. Sarcoma 2012, 2012:152382.
-
(2012)
Sarcoma
, vol.2012
, pp. 152382
-
-
Calvert, G.T.1
Randall, R.L.2
Jones, K.B.3
-
17
-
-
20144381477
-
TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study
-
Wunder J.S., Gokgoz N., Parkes R., et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. JClin Oncol 2005, 23(7):1483-1490.
-
(2005)
JClin Oncol
, vol.23
, Issue.7
, pp. 1483-1490
-
-
Wunder, J.S.1
Gokgoz, N.2
Parkes, R.3
-
18
-
-
84355166531
-
Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes
-
Duhamel L.A., Ye H., Halai D., et al. Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology 2012, 60(2):357-359.
-
(2012)
Histopathology
, vol.60
, Issue.2
, pp. 357-359
-
-
Duhamel, L.A.1
Ye, H.2
Halai, D.3
-
19
-
-
84865127671
-
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer
-
Lenos K., Grawenda A.M., Lodder K., et al. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Res 2012, 72(16):4074-4084.
-
(2012)
Cancer Res
, vol.72
, Issue.16
, pp. 4074-4084
-
-
Lenos, K.1
Grawenda, A.M.2
Lodder, K.3
-
20
-
-
10744221485
-
Invivo activation of the p53 pathway by small-molecule antagonists of MDM2
-
Vassilev L.T., Vu B.T., Graves B., et al. Invivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303(5659):844-848.
-
(2004)
Science
, vol.303
, Issue.5659
, pp. 844-848
-
-
Vassilev, L.T.1
Vu, B.T.2
Graves, B.3
-
21
-
-
50149120366
-
Cellular mechanisms of tumour suppression by the retinoblastoma gene
-
Burkhart D.L., Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008, 8(9):671-682.
-
(2008)
Nat Rev Cancer
, vol.8
, Issue.9
, pp. 671-682
-
-
Burkhart, D.L.1
Sage, J.2
-
22
-
-
58049202910
-
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up
-
Marees T., Moll A.C., Imhof S.M., et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. JNatl Cancer Inst 2008, 100(24):1771-1779.
-
(2008)
JNatl Cancer Inst
, vol.100
, Issue.24
, pp. 1771-1779
-
-
Marees, T.1
Moll, A.C.2
Imhof, S.M.3
-
23
-
-
0038221272
-
Genetic and epigenetic alterations ofthe cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas
-
Patino-Garcia A., Pineiro E.S., Diez M.Z., et al. Genetic and epigenetic alterations ofthe cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas. JPediatr Hematol Oncol 2003, 25(5):362-367.
-
(2003)
JPediatr Hematol Oncol
, vol.25
, Issue.5
, pp. 362-367
-
-
Patino-Garcia, A.1
Pineiro, E.S.2
Diez, M.Z.3
-
24
-
-
0031421683
-
Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas
-
Pellin A., Boix-Ferrero J., Carpio D., et al. Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. Diagn Mol Pathol 1997, 6(6):333-341.
-
(1997)
Diagn Mol Pathol
, vol.6
, Issue.6
, pp. 333-341
-
-
Pellin, A.1
Boix-Ferrero, J.2
Carpio, D.3
-
25
-
-
0033595635
-
Alteration of pRb/p16/cdk4 regulation in human osteosarcoma
-
Benassi M.S., Molendini L., Gamberi G., et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer 1999, 84(5):489-493.
-
(1999)
Int J Cancer
, vol.84
, Issue.5
, pp. 489-493
-
-
Benassi, M.S.1
Molendini, L.2
Gamberi, G.3
-
26
-
-
34447326491
-
Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma
-
Heinsohn S., Evermann U., Zur S.U., et al. Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol 2007, 30(5):1205-1214.
-
(2007)
Int J Oncol
, vol.30
, Issue.5
, pp. 1205-1214
-
-
Heinsohn, S.1
Evermann, U.2
Zur, S.U.3
-
27
-
-
0036386059
-
Retinoblastoma tumor suppressor and genome stability
-
Zheng L., Lee W.H. Retinoblastoma tumor suppressor and genome stability. Adv Cancer Res 2002, 85:13-50.
-
(2002)
Adv Cancer Res
, vol.85
, pp. 13-50
-
-
Zheng, L.1
Lee, W.H.2
-
28
-
-
33750906287
-
Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity
-
Knudsen E.S., Sexton C.R., Mayhew C.N. Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Curr Mol Med 2006, 6(7):749-757.
-
(2006)
Curr Mol Med
, vol.6
, Issue.7
, pp. 749-757
-
-
Knudsen, E.S.1
Sexton, C.R.2
Mayhew, C.N.3
-
29
-
-
70350457821
-
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2
-
Mohseny A.B., Szuhai K., Romeo S., et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. JPathol 2009, 219(3):294-305.
-
(2009)
JPathol
, vol.219
, Issue.3
, pp. 294-305
-
-
Mohseny, A.B.1
Szuhai, K.2
Romeo, S.3
-
30
-
-
79952199693
-
Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma
-
Mohseny A.B., Tieken C., Van der Velden P.A., et al. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer 2010, 49(12):1095-1103.
-
(2010)
Genes Chromosomes Cancer
, vol.49
, Issue.12
, pp. 1095-1103
-
-
Mohseny, A.B.1
Tieken, C.2
Van der Velden, P.A.3
-
31
-
-
0036342469
-
Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma
-
Holcombe R.F., Marsh J.L., Waterman M.L., et al. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 2002, 55(4):220-226.
-
(2002)
Mol Pathol
, vol.55
, Issue.4
, pp. 220-226
-
-
Holcombe, R.F.1
Marsh, J.L.2
Waterman, M.L.3
-
32
-
-
84863011082
-
Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells
-
Wan X., Liu J., Lu J.F., et al. Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 2012, 18(3):726-736.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.3
, pp. 726-736
-
-
Wan, X.1
Liu, J.2
Lu, J.F.3
-
33
-
-
0036888309
-
Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma
-
Haydon R.C., Deyrup A., Ishikawa A., et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002, 102(4):338-342.
-
(2002)
Int J Cancer
, vol.102
, Issue.4
, pp. 338-342
-
-
Haydon, R.C.1
Deyrup, A.2
Ishikawa, A.3
-
34
-
-
70649090109
-
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
-
Cleton-Jansen A.M., Anninga J.K., Briaire-de Bruijn I.H., et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 2009, 101(11):1909-1918.
-
(2009)
Br J Cancer
, vol.101
, Issue.11
, pp. 1909-1918
-
-
Cleton-Jansen, A.M.1
Anninga, J.K.2
Briaire-de Bruijn, I.H.3
-
35
-
-
73649132981
-
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma
-
Cai Y., Mohseny A.B., Karperien M., et al. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. JPathol 2010, 220:24-33.
-
(2010)
JPathol
, vol.220
, pp. 24-33
-
-
Cai, Y.1
Mohseny, A.B.2
Karperien, M.3
-
36
-
-
70349101267
-
Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling
-
Enomoto M., Hayakawa S., Itsukushima S., et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 2009, 28(36):3197-3208.
-
(2009)
Oncogene
, vol.28
, Issue.36
, pp. 3197-3208
-
-
Enomoto, M.1
Hayakawa, S.2
Itsukushima, S.3
-
37
-
-
67449103899
-
Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma
-
Morioka K., Tanikawa C., Ochi K., et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci 2009, 100(7):1227-1233.
-
(2009)
Cancer Sci
, vol.100
, Issue.7
, pp. 1227-1233
-
-
Morioka, K.1
Tanikawa, C.2
Ochi, K.3
-
38
-
-
84869488840
-
The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma
-
Mohseny A.B., Cai Y., Kuijjer M., et al. The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. Eur J Cancer 2012, 48(18):3429-3438.
-
(2012)
Eur J Cancer
, vol.48
, Issue.18
, pp. 3429-3438
-
-
Mohseny, A.B.1
Cai, Y.2
Kuijjer, M.3
-
39
-
-
0027423419
-
Role of insulin-like growth factors in embryonic and postnatal growth
-
Baker J., Liu J.P., Robertson E.J., et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75(1):73-82.
-
(1993)
Cell
, vol.75
, Issue.1
, pp. 73-82
-
-
Baker, J.1
Liu, J.P.2
Robertson, E.J.3
-
40
-
-
79951860072
-
Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer
-
Maki R.G. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. JClin Oncol 2010, 28(33):4985-4995.
-
(2010)
JClin Oncol
, vol.28
, Issue.33
, pp. 4985-4995
-
-
Maki, R.G.1
-
41
-
-
67649389647
-
Development of IGF-IR inhibitors in pediatric sarcomas
-
Kolb E.A., Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep 2009, 11(4):307-313.
-
(2009)
Curr Oncol Rep
, vol.11
, Issue.4
, pp. 307-313
-
-
Kolb, E.A.1
Gorlick, R.2
-
42
-
-
42349083307
-
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program
-
Kolb E.A., Gorlick R., Houghton P.J., et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50(6):1190-1197.
-
(2008)
Pediatr Blood Cancer
, vol.50
, Issue.6
, pp. 1190-1197
-
-
Kolb, E.A.1
Gorlick, R.2
Houghton, P.J.3
-
43
-
-
77953256426
-
R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts
-
Kolb E.A., Kamara D., Zhang W., et al. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 2010, 55(1):67-75.
-
(2010)
Pediatr Blood Cancer
, vol.55
, Issue.1
, pp. 67-75
-
-
Kolb, E.A.1
Kamara, D.2
Zhang, W.3
-
44
-
-
84863278693
-
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program
-
Kolb E.A., Gorlick R., Maris J.M., et al. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2012, 58(5):729-735.
-
(2012)
Pediatr Blood Cancer
, vol.58
, Issue.5
, pp. 729-735
-
-
Kolb, E.A.1
Gorlick, R.2
Maris, J.M.3
-
45
-
-
0343628689
-
Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma
-
Sulzbacher I., Traxler M., Mosberger I., et al. Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000, 13(6):632-637.
-
(2000)
Mod Pathol
, vol.13
, Issue.6
, pp. 632-637
-
-
Sulzbacher, I.1
Traxler, M.2
Mosberger, I.3
-
46
-
-
43049095679
-
Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
-
Kubo T., Piperdi S., Rosenblum J., et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008, 112(10):2119-2129.
-
(2008)
Cancer
, vol.112
, Issue.10
, pp. 2119-2129
-
-
Kubo, T.1
Piperdi, S.2
Rosenblum, J.3
-
47
-
-
78649261532
-
Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome
-
Sulzbacher I., Birner P., Dominkus M., et al. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome. Pathology 2010, 42(7):664-668.
-
(2010)
Pathology
, vol.42
, Issue.7
, pp. 664-668
-
-
Sulzbacher, I.1
Birner, P.2
Dominkus, M.3
-
48
-
-
34447323857
-
Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker
-
Sulzbacher I., Birner P., Toma C., et al. Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker. JClin Pathol 2007, 60(7):804-807.
-
(2007)
JClin Pathol
, vol.60
, Issue.7
, pp. 804-807
-
-
Sulzbacher, I.1
Birner, P.2
Toma, C.3
-
49
-
-
74549210540
-
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
-
Pignochino Y., Grignani G., Cavalloni G., et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009, 8:118.
-
(2009)
Mol Cancer
, vol.8
, pp. 118
-
-
Pignochino, Y.1
Grignani, G.2
Cavalloni, G.3
-
50
-
-
84871610443
-
SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells
-
Wang C.T., Lin C.S., Shiau C.W., et al. SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells. JOrthop Res 2013, 31(2):335-342.
-
(2013)
JOrthop Res
, vol.31
, Issue.2
, pp. 335-342
-
-
Wang, C.T.1
Lin, C.S.2
Shiau, C.W.3
-
51
-
-
84856343533
-
Aphase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
-
Grignani G., Palmerini E., Dileo P., et al. Aphase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012, 23(2):508-516.
-
(2012)
Ann Oncol
, vol.23
, Issue.2
, pp. 508-516
-
-
Grignani, G.1
Palmerini, E.2
Dileo, P.3
-
52
-
-
58149232649
-
Unraveling the biologic and clinical complexities of HER2
-
Park J.W., Neve R.M., Szollosi J., et al. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 2008, 8(5):392-401.
-
(2008)
Clin Breast Cancer
, vol.8
, Issue.5
, pp. 392-401
-
-
Park, J.W.1
Neve, R.M.2
Szollosi, J.3
-
53
-
-
84857826438
-
The human epidermal growth factor receptor 2 (HER2)
-
Tafe L.J., Tsongalis G.J. The human epidermal growth factor receptor 2 (HER2). Clin Chem Lab Med 2012, 50(1):23-30.
-
(2012)
Clin Chem Lab Med
, vol.50
, Issue.1
, pp. 23-30
-
-
Tafe, L.J.1
Tsongalis, G.J.2
-
54
-
-
0035169109
-
Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma
-
Morris C.D., Gorlick R., Huvos G., et al. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 2001, 382:59-65.
-
(2001)
Clin Orthop Relat Res
, vol.382
, pp. 59-65
-
-
Morris, C.D.1
Gorlick, R.2
Huvos, G.3
-
55
-
-
20444501794
-
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma
-
Scotlandi K., Manara M.C., Hattinger C.M., et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005, 41(9):1349-1361.
-
(2005)
Eur J Cancer
, vol.41
, Issue.9
, pp. 1349-1361
-
-
Scotlandi, K.1
Manara, M.C.2
Hattinger, C.M.3
-
56
-
-
84864044404
-
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group
-
Ebb D., Meyers P., Grier H., et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. JClin Oncol 2012, 30(20):2545-2551.
-
(2012)
JClin Oncol
, vol.30
, Issue.20
, pp. 2545-2551
-
-
Ebb, D.1
Meyers, P.2
Grier, H.3
-
57
-
-
1942453293
-
Overexpression of the Her-2 oncogene does not play a role in high-grade osteosarcomas
-
Anninga J.K., Van de Vijver M.J., Cleton-Jansen A.M., et al. Overexpression of the Her-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004, 40:963-970.
-
(2004)
Eur J Cancer
, vol.40
, pp. 963-970
-
-
Anninga, J.K.1
Van de Vijver, M.J.2
Cleton-Jansen, A.M.3
-
58
-
-
27844591419
-
HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study
-
Somers G.R., Ho M., Zielenska M., et al. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 2005, 8(5):525-532.
-
(2005)
Pediatr Dev Pathol
, vol.8
, Issue.5
, pp. 525-532
-
-
Somers, G.R.1
Ho, M.2
Zielenska, M.3
-
59
-
-
33646714910
-
Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions
-
Willmore-Payne C., Holden J.A., Zhou H., et al. Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions. Arch Pathol Lab Med 2006, 130(5):691-698.
-
(2006)
Arch Pathol Lab Med
, vol.130
, Issue.5
, pp. 691-698
-
-
Willmore-Payne, C.1
Holden, J.A.2
Zhou, H.3
-
60
-
-
0026060863
-
The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893
-
Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991, (262):3-11.
-
(1991)
Clin Orthop Relat Res
, Issue.262
, pp. 3-11
-
-
Coley, W.B.1
-
61
-
-
42149099408
-
Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms
-
Biswas S.K., Sica A., Lewis C.E. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. JImmunol 2008, 180(4):2011-2017.
-
(2008)
JImmunol
, vol.180
, Issue.4
, pp. 2011-2017
-
-
Biswas, S.K.1
Sica, A.2
Lewis, C.E.3
-
63
-
-
79954573473
-
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents
-
Buddingh' E.P., Kuijjer M.L., Duim R.A., et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents. Clin Cancer Res 2011, 17:2010-2019.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2010-2019
-
-
Buddingh', E.P.1
Kuijjer, M.L.2
Duim, R.A.3
-
64
-
-
39149136228
-
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group
-
Meyers P.A., Schwartz C.L., Krailo M.D., et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. JClin Oncol 2008, 26(4):633-638.
-
(2008)
JClin Oncol
, vol.26
, Issue.4
, pp. 633-638
-
-
Meyers, P.A.1
Schwartz, C.L.2
Krailo, M.D.3
-
65
-
-
46449091809
-
Osteosarcoma: the same old drugs or more?
-
Bielack S.S., Marina N., Ferrari S., et al. Osteosarcoma: the same old drugs or more?. JClin Oncol 2008, 26(18):3102-3103.
-
(2008)
JClin Oncol
, vol.26
, Issue.18
, pp. 3102-3103
-
-
Bielack, S.S.1
Marina, N.2
Ferrari, S.3
-
66
-
-
84866596020
-
Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
ESMO/European Sarcoma Network Working Group
-
ESMO/European Sarcoma Network Working Group Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl 7):vii100-vii109.
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL 7
, pp. 7100-7109
-
-
-
67
-
-
79953805065
-
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells
-
Buddingh E.P., Schilham M.W., Ruslan S.E., et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 2011, 60(4):575-586.
-
(2011)
Cancer Immunol Immunother
, vol.60
, Issue.4
, pp. 575-586
-
-
Buddingh, E.P.1
Schilham, M.W.2
Ruslan, S.E.3
-
68
-
-
84856015456
-
Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma
-
Pahl J.H., Ruslan S.E., Buddingh E.P., et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 2012, 18(2):432-441.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.2
, pp. 432-441
-
-
Pahl, J.H.1
Ruslan, S.E.2
Buddingh, E.P.3
-
69
-
-
0026670898
-
Taxol increases steady-state levels oflipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages
-
Manthey C.L., Brandes M.E., Perera P.Y., et al. Taxol increases steady-state levels oflipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. JImmunol 1992, 149(7):2459-2465.
-
(1992)
JImmunol
, vol.149
, Issue.7
, pp. 2459-2465
-
-
Manthey, C.L.1
Brandes, M.E.2
Perera, P.Y.3
-
70
-
-
0024341856
-
Effect of human interferon-alpha and interferon-gamma on growth, histology, and DNA content of human osteosarcomas in nude mice
-
Brosjo O., Bauer H.C., Nilsson O.S., et al. Effect of human interferon-alpha and interferon-gamma on growth, histology, and DNA content of human osteosarcomas in nude mice. JInterferon Res 1989, 9(4):475-489.
-
(1989)
JInterferon Res
, vol.9
, Issue.4
, pp. 475-489
-
-
Brosjo, O.1
Bauer, H.C.2
Nilsson, O.S.3
-
71
-
-
23944474283
-
Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series
-
Muller C.R., Smeland S., Bauer H.C., et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 2005, 44(5):475-480.
-
(2005)
Acta Oncol
, vol.44
, Issue.5
, pp. 475-480
-
-
Muller, C.R.1
Smeland, S.2
Bauer, H.C.3
-
72
-
-
0018972569
-
Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma: case reports
-
Ito H., Murakami K., Yanagawa T., et al. Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma: case reports. Cancer 1980, 46(7):1562-1565.
-
(1980)
Cancer
, vol.46
, Issue.7
, pp. 1562-1565
-
-
Ito, H.1
Murakami, K.2
Yanagawa, T.3
-
73
-
-
0023368740
-
Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas
-
Edmonson J.H., Long H.J., Frytak S., et al. Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas. Cancer Treat Rep 1987, 71(7-8):747-748.
-
(1987)
Cancer Treat Rep
, vol.71
, Issue.7-8
, pp. 747-748
-
-
Edmonson, J.H.1
Long, H.J.2
Frytak, S.3
-
74
-
-
77955122716
-
Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group
-
Arndt C.A., Koshkina N.V., Inwards C.Y., et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group. Clin Cancer Res 2010, 16(15):4024-4030.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.15
, pp. 4024-4030
-
-
Arndt, C.A.1
Koshkina, N.V.2
Inwards, C.Y.3
-
75
-
-
0030844897
-
Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma
-
Worth L.L., Jaffe N., Benjamin R.S., et al. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res 1997, 3(10):1721-1729.
-
(1997)
Clin Cancer Res
, vol.3
, Issue.10
, pp. 1721-1729
-
-
Worth, L.L.1
Jaffe, N.2
Benjamin, R.S.3
-
76
-
-
46749098526
-
T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55
-
Ullenhag G.J., Spendlove I., Watson N.F., et al. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol 2008, 128(2):148-154.
-
(2008)
Clin Immunol
, vol.128
, Issue.2
, pp. 148-154
-
-
Ullenhag, G.J.1
Spendlove, I.2
Watson, N.F.3
-
77
-
-
78650304661
-
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class
-
Clezardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011, 48(1):71-79.
-
(2011)
Bone
, vol.48
, Issue.1
, pp. 71-79
-
-
Clezardin, P.1
-
78
-
-
79952246410
-
Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells
-
Nilsson S., Huelsenbeck J., Fritz G. Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells. Cancer Lett 2011, 304(1):60-69.
-
(2011)
Cancer Lett
, vol.304
, Issue.1
, pp. 60-69
-
-
Nilsson, S.1
Huelsenbeck, J.2
Fritz, G.3
-
79
-
-
33745040807
-
Anticancer effects of zoledronic acid against human osteosarcoma cells
-
Kubista B., Trieb K., Sevelda F., et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. JOrthop Res 2006, 24(6):1145-1152.
-
(2006)
JOrthop Res
, vol.24
, Issue.6
, pp. 1145-1152
-
-
Kubista, B.1
Trieb, K.2
Sevelda, F.3
-
80
-
-
33947540949
-
Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells
-
Molinuevo M.S., Bruzzone L., Cortizo A.M. Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells. Eur J Pharmacol 2007, 562(1-2):28-33.
-
(2007)
Eur J Pharmacol
, vol.562
, Issue.1-2
, pp. 28-33
-
-
Molinuevo, M.S.1
Bruzzone, L.2
Cortizo, A.M.3
-
81
-
-
28044467108
-
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice
-
Ory B., Heymann M.F., Kamijo A., et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005, 104(11):2522-2529.
-
(2005)
Cancer
, vol.104
, Issue.11
, pp. 2522-2529
-
-
Ory, B.1
Heymann, M.F.2
Kamijo, A.3
-
82
-
-
79953783840
-
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
-
Meyers P.A., Healey J.H., Chou A.J., et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 2011, 117(8):1736-1744.
-
(2011)
Cancer
, vol.117
, Issue.8
, pp. 1736-1744
-
-
Meyers, P.A.1
Healey, J.H.2
Chou, A.J.3
-
83
-
-
0017695360
-
Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading
-
Evans H.L., Ayala A.G., Romsdahl M.M. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977, 40:818-831.
-
(1977)
Cancer
, vol.40
, pp. 818-831
-
-
Evans, H.L.1
Ayala, A.G.2
Romsdahl, M.M.3
-
84
-
-
84884982234
-
Dedifferentiated chondrosarcoma
-
IARC Press, Lyon, C.D. Fletcher, J.A. Bridge, P.C. Hogendoorn (Eds.)
-
Inwards C.Y., Hogendoorn P.C. Dedifferentiated chondrosarcoma. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone 2013, 269-270. IARC Press, Lyon. 4th edition. C.D. Fletcher, J.A. Bridge, P.C. Hogendoorn (Eds.).
-
(2013)
World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone
, pp. 269-270
-
-
Inwards, C.Y.1
Hogendoorn, P.C.2
-
85
-
-
0344887930
-
Mesenchymal chondrosarcoma
-
IARC Press, Lyon, C.D. Fletcher, J.A. Bridge, P.C. Hogendoorn (Eds.)
-
Nakashima Y., de Pinieux G., Ladanyi M. Mesenchymal chondrosarcoma. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone 2013, 271-272. IARC Press, Lyon. C.D. Fletcher, J.A. Bridge, P.C. Hogendoorn (Eds.).
-
(2013)
World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone
, pp. 271-272
-
-
Nakashima, Y.1
de Pinieux, G.2
Ladanyi, M.3
-
86
-
-
84988606085
-
Clear cell chondrosarcoma
-
IARC Press, Lyon, C.D. Fletcher, J.A. Bridge, P.C. Hogendoorn (Eds.)
-
McCarthy E.F., Hogendoorn P.C. Clear cell chondrosarcoma. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone 2013, 273-274. IARC Press, Lyon. 4th edition. C.D. Fletcher, J.A. Bridge, P.C. Hogendoorn (Eds.).
-
(2013)
World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone
, pp. 273-274
-
-
McCarthy, E.F.1
Hogendoorn, P.C.2
-
87
-
-
84863559996
-
Low-grade chondrosarcoma of long bones treated with intralesional curettage followed by application of phenol, ethanol, and bone-grafting
-
Verdegaal S.H., Brouwers H.F., van Zwet E.W., et al. Low-grade chondrosarcoma of long bones treated with intralesional curettage followed by application of phenol, ethanol, and bone-grafting. JBone Joint Surg Am 2012, 94(13):1201-1207.
-
(2012)
JBone Joint Surg Am
, vol.94
, Issue.13
, pp. 1201-1207
-
-
Verdegaal, S.H.1
Brouwers, H.F.2
van Zwet, E.W.3
-
88
-
-
84859381932
-
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003
-
Fox E., Patel S., Wathen J.K., et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 2012, 17(3):321-e329.
-
(2012)
Oncologist
, vol.17
, Issue.3
-
-
Fox, E.1
Patel, S.2
Wathen, J.K.3
-
89
-
-
84871857791
-
Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute
-
Yokota K., Sakamoto A., Matsumoto Y., et al. Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute. JOrthop Surg Res 2012, 7(1):38.
-
(2012)
JOrthop Surg Res
, vol.7
, Issue.1
, pp. 38
-
-
Yokota, K.1
Sakamoto, A.2
Matsumoto, Y.3
-
90
-
-
77954030485
-
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets
-
Bovée J.V., Hogendoorn P.C., Wunder J.S., et al. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010, 10(7):481-488.
-
(2010)
Nat Rev Cancer
, vol.10
, Issue.7
, pp. 481-488
-
-
Bovée, J.V.1
Hogendoorn, P.C.2
Wunder, J.S.3
-
91
-
-
80052668046
-
The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets
-
David E., Blanchard F., Heymann M.F., et al. The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets. Sarcoma 2011, 2011:932451.
-
(2011)
Sarcoma
, vol.2011
, pp. 932451
-
-
David, E.1
Blanchard, F.2
Heymann, M.F.3
-
92
-
-
84861723964
-
Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma invitro: BCL-2 family members cause chemoresistance
-
van Oosterwijk J.G., Herpers B., Meijer D., et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma invitro: BCL-2 family members cause chemoresistance. Ann Oncol 2012, 23(6):1617-1626.
-
(2012)
Ann Oncol
, vol.23
, Issue.6
, pp. 1617-1626
-
-
van Oosterwijk, J.G.1
Herpers, B.2
Meijer, D.3
-
93
-
-
84871731169
-
Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors
-
Schaap F.G., French P.J., Bovee J.V. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors. Adv Anat Pathol 2013, 20(1):32-38.
-
(2013)
Adv Anat Pathol
, vol.20
, Issue.1
, pp. 32-38
-
-
Schaap, F.G.1
French, P.J.2
Bovee, J.V.3
-
94
-
-
84864755321
-
Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma
-
Meijer D., de J.D., Pansuriya T.C., et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer 2012, 51(10):899-909.
-
(2012)
Genes Chromosomes Cancer
, vol.51
, Issue.10
, pp. 899-909
-
-
Meijer, D.1
de, J.D.2
Pansuriya, T.C.3
-
95
-
-
82255183048
-
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
-
Pansuriya T.C., van E.R., d'Adamo P., et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011, 43(12):1256-1261.
-
(2011)
Nat Genet
, vol.43
, Issue.12
, pp. 1256-1261
-
-
Pansuriya, T.C.1
van, E.R.2
d'Adamo, P.3
-
96
-
-
79958226901
-
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
-
Amary M.F., Bacsi K., Maggiani F., et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. JPathol 2011, 224(3):334-343.
-
(2011)
JPathol
, vol.224
, Issue.3
, pp. 334-343
-
-
Amary, M.F.1
Bacsi, K.2
Maggiani, F.3
-
97
-
-
82255183051
-
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
-
Amary M.F., Damato S., Halai D., et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011, 43(12):1262-1265.
-
(2011)
Nat Genet
, vol.43
, Issue.12
, pp. 1262-1265
-
-
Amary, M.F.1
Damato, S.2
Halai, D.3
-
98
-
-
84355162850
-
IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas
-
Damato S., Alorjani M., Bonar F., et al. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology 2012, 60(2):363-365.
-
(2012)
Histopathology
, vol.60
, Issue.2
, pp. 363-365
-
-
Damato, S.1
Alorjani, M.2
Bonar, F.3
-
99
-
-
84860378609
-
Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation
-
Leonardi R., Subramanian C., Jackowski S., et al. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. JBiol Chem 2012, 287(18):14615-14620.
-
(2012)
JBiol Chem
, vol.287
, Issue.18
, pp. 14615-14620
-
-
Leonardi, R.1
Subramanian, C.2
Jackowski, S.3
-
100
-
-
64849098267
-
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha
-
Zhao S., Lin Y., Xu W., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324(5924):261-265.
-
(2009)
Science
, vol.324
, Issue.5924
, pp. 261-265
-
-
Zhao, S.1
Lin, Y.2
Xu, W.3
-
101
-
-
72049125350
-
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
-
Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462(7274):739-744.
-
(2009)
Nature
, vol.462
, Issue.7274
, pp. 739-744
-
-
Dang, L.1
White, D.W.2
Gross, S.3
-
102
-
-
84859553853
-
An invivo patient-derived model of endogenous IDH1-mutant glioma
-
Luchman H.A., Stechishin O.D., Dang N.H., et al. An invivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 2012, 14(2):184-191.
-
(2012)
Neuro Oncol
, vol.14
, Issue.2
, pp. 184-191
-
-
Luchman, H.A.1
Stechishin, O.D.2
Dang, N.H.3
-
103
-
-
77649305610
-
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
-
Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17(3):225-234.
-
(2010)
Cancer Cell
, vol.17
, Issue.3
, pp. 225-234
-
-
Ward, P.S.1
Patel, J.2
Wise, D.R.3
-
104
-
-
77956265489
-
IDH mutations in glioma and acute myeloid leukemia
-
Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010, 16(9):387-397.
-
(2010)
Trends Mol Med
, vol.16
, Issue.9
, pp. 387-397
-
-
Dang, L.1
Jin, S.2
Su, S.M.3
-
105
-
-
78650019179
-
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
-
Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18(6):553-567.
-
(2010)
Cancer Cell
, vol.18
, Issue.6
, pp. 553-567
-
-
Figueroa, M.E.1
Abdel-Wahab, O.2
Lu, C.3
-
106
-
-
69949114447
-
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
-
Hartmann C., Meyer J., Balss J., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009, 118(4):469-474.
-
(2009)
Acta Neuropathol
, vol.118
, Issue.4
, pp. 469-474
-
-
Hartmann, C.1
Meyer, J.2
Balss, J.3
-
107
-
-
67449099808
-
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
-
Kang M.R., Kim M.S., Oh J.E., et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009, 125(2):353-355.
-
(2009)
Int J Cancer
, vol.125
, Issue.2
, pp. 353-355
-
-
Kang, M.R.1
Kim, M.S.2
Oh, J.E.3
-
108
-
-
77949262337
-
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer
-
Murugan A.K., Bojdani E., Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 2010, 393(3):555-559.
-
(2010)
Biochem Biophys Res Commun
, vol.393
, Issue.3
, pp. 555-559
-
-
Murugan, A.K.1
Bojdani, E.2
Xing, M.3
-
109
-
-
60849115270
-
IDH1 and IDH2 mutations in gliomas
-
Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. NEngl J Med 2009, 360(8):765-773.
-
(2009)
NEngl J Med
, vol.360
, Issue.8
, pp. 765-773
-
-
Yan, H.1
Parsons, D.W.2
Jin, G.3
-
110
-
-
77952108366
-
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma
-
Noushmehr H., Weisenberger D.J., Diefes K., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17(5):510-522.
-
(2010)
Cancer Cell
, vol.17
, Issue.5
, pp. 510-522
-
-
Noushmehr, H.1
Weisenberger, D.J.2
Diefes, K.3
-
111
-
-
84858796262
-
IDH mutation impairs histone demethylation and results in a block to cell differentiation
-
Lu C., Ward P.S., Kapoor G.S., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483(7390):474-478.
-
(2012)
Nature
, vol.483
, Issue.7390
, pp. 474-478
-
-
Lu, C.1
Ward, P.S.2
Kapoor, G.S.3
-
112
-
-
84866480031
-
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function
-
Sasaki M., Knobbe C.B., Itsumi M., et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 2012, 26(18):2038-2049.
-
(2012)
Genes Dev
, vol.26
, Issue.18
, pp. 2038-2049
-
-
Sasaki, M.1
Knobbe, C.B.2
Itsumi, M.3
-
113
-
-
84862776918
-
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
-
Koivunen P., Lee S., Duncan C.G., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483(7390):484-488.
-
(2012)
Nature
, vol.483
, Issue.7390
, pp. 484-488
-
-
Koivunen, P.1
Lee, S.2
Duncan, C.G.3
-
114
-
-
84861845402
-
The updated biology of hypoxia-inducible factor
-
Greer S.N., Metcalf J.L., Wang Y., et al. The updated biology of hypoxia-inducible factor. EMBO J 2012, 31(11):2448-2460.
-
(2012)
EMBO J
, vol.31
, Issue.11
, pp. 2448-2460
-
-
Greer, S.N.1
Metcalf, J.L.2
Wang, Y.3
-
115
-
-
18644366801
-
Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors
-
Robey I.F., Lien A.D., Welsh S.J., et al. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 2005, 7(4):324-330.
-
(2005)
Neoplasia
, vol.7
, Issue.4
, pp. 324-330
-
-
Robey, I.F.1
Lien, A.D.2
Welsh, S.J.3
-
116
-
-
33748152298
-
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression
-
O'Donnell J.L., Joyce M.R., Shannon A.M., et al. Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression. Cancer Treat Rev 2006, 32(6):407-416.
-
(2006)
Cancer Treat Rev
, vol.32
, Issue.6
, pp. 407-416
-
-
O'Donnell, J.L.1
Joyce, M.R.2
Shannon, A.M.3
-
117
-
-
0035413326
-
HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis
-
Fang J., Yan L., Shing Y., et al. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001, 61(15):5731-5735.
-
(2001)
Cancer Res
, vol.61
, Issue.15
, pp. 5731-5735
-
-
Fang, J.1
Yan, L.2
Shing, Y.3
-
118
-
-
4844228509
-
Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes
-
Lin C., McGough R., Aswad B., et al. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. JOrthop Res 2004, 22(6):1175-1181.
-
(2004)
JOrthop Res
, vol.22
, Issue.6
, pp. 1175-1181
-
-
Lin, C.1
McGough, R.2
Aswad, B.3
-
119
-
-
77950477521
-
Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours
-
Boeuf S., Bovee J.V., Lehner B., et al. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology 2010, 56(5):641-651.
-
(2010)
Histopathology
, vol.56
, Issue.5
, pp. 641-651
-
-
Boeuf, S.1
Bovee, J.V.2
Lehner, B.3
-
120
-
-
84876880959
-
Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer
-
Agani F., Jiang B.H. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets 2013, 13(3):245-251.
-
(2013)
Curr Cancer Drug Targets
, vol.13
, Issue.3
, pp. 245-251
-
-
Agani, F.1
Jiang, B.H.2
-
121
-
-
34247371033
-
Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy
-
Maddika S., Ande S.R., Panigrahi S., et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007, 10(1-2):13-29.
-
(2007)
Drug Resist Updat
, vol.10
, Issue.1-2
, pp. 13-29
-
-
Maddika, S.1
Ande, S.R.2
Panigrahi, S.3
-
122
-
-
68049148657
-
Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment
-
Schrage Y.M., Briaire-de Bruijn I.H., de Miranda N.F., et al. Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment. Cancer Res 2009, 69(15):6216-6222.
-
(2009)
Cancer Res
, vol.69
, Issue.15
, pp. 6216-6222
-
-
Schrage, Y.M.1
Briaire-de Bruijn, I.H.2
de Miranda, N.F.3
-
123
-
-
33646270906
-
Cartducin stimulates mesenchymal chondroprogenitor cell proliferation through both extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways
-
Akiyama H., Furukawa S., Wakisaka S., et al. Cartducin stimulates mesenchymal chondroprogenitor cell proliferation through both extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways. FEBS J 2006, 273(10):2257-2263.
-
(2006)
FEBS J
, vol.273
, Issue.10
, pp. 2257-2263
-
-
Akiyama, H.1
Furukawa, S.2
Wakisaka, S.3
-
124
-
-
79955383070
-
Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways
-
Ikegami D., Akiyama H., Suzuki A., et al. Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways. Development 2011, 138(8):1507-1519.
-
(2011)
Development
, vol.138
, Issue.8
, pp. 1507-1519
-
-
Ikegami, D.1
Akiyama, H.2
Suzuki, A.3
-
125
-
-
78549284980
-
Sox9 expression is not limited to chondroid neoplasms: variable occurrence in other soft tissue and bone tumors with frequent expression by synovial sarcomas
-
Cajaiba M.M., Jianhua L., Goodman M.A., et al. Sox9 expression is not limited to chondroid neoplasms: variable occurrence in other soft tissue and bone tumors with frequent expression by synovial sarcomas. Int J Surg Pathol 2010, 18(5):319-323.
-
(2010)
Int J Surg Pathol
, vol.18
, Issue.5
, pp. 319-323
-
-
Cajaiba, M.M.1
Jianhua, L.2
Goodman, M.A.3
-
126
-
-
0037343473
-
Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors
-
Wehrli B.M., Huang W., De C.B., et al. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 2003, 34(3):263-269.
-
(2003)
Hum Pathol
, vol.34
, Issue.3
, pp. 263-269
-
-
Wehrli, B.M.1
Huang, W.2
De, C.B.3
-
127
-
-
0036183251
-
PTEN mutation is rare in chondrosarcoma
-
Lin C., Meitner P.A., Terek R.M. PTEN mutation is rare in chondrosarcoma. Diagn Mol Pathol 2002, 11(1):22-26.
-
(2002)
Diagn Mol Pathol
, vol.11
, Issue.1
, pp. 22-26
-
-
Lin, C.1
Meitner, P.A.2
Terek, R.M.3
-
128
-
-
0038797781
-
Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications
-
Brown R.E., Boyle J.L. Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications. Ann Clin Lab Sci 2003, 33(2):131-141.
-
(2003)
Ann Clin Lab Sci
, vol.33
, Issue.2
, pp. 131-141
-
-
Brown, R.E.1
Boyle, J.L.2
-
129
-
-
84862979856
-
Inhibition of chondrosarcoma growth by mTOR inhibitor in an invivo syngeneic rat model
-
Perez J., Decouvelaere A.V., Pointecouteau T., et al. Inhibition of chondrosarcoma growth by mTOR inhibitor in an invivo syngeneic rat model. PLoS One 2012, 7(6):e32458.
-
(2012)
PLoS One
, vol.7
, Issue.6
-
-
Perez, J.1
Decouvelaere, A.V.2
Pointecouteau, T.3
-
130
-
-
80054785459
-
Amechanism for synergy with combined mTOR and PI3 kinase inhibitors
-
Yang S., Xiao X., Meng X., et al. Amechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 2011, 6(10):e26343.
-
(2011)
PLoS One
, vol.6
, Issue.10
-
-
Yang, S.1
Xiao, X.2
Meng, X.3
-
131
-
-
84871207566
-
Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas
-
Bernstein-Molho R., Kollender Y., Issakov J., et al. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas. Cancer Chemother Pharmacol 2012, 70(6):855-860.
-
(2012)
Cancer Chemother Pharmacol
, vol.70
, Issue.6
, pp. 855-860
-
-
Bernstein-Molho, R.1
Kollender, Y.2
Issakov, J.3
-
132
-
-
0037080135
-
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis
-
Aligayer H., Boyd D.D., Heiss M.M., et al. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002, 94(2):344-351.
-
(2002)
Cancer
, vol.94
, Issue.2
, pp. 344-351
-
-
Aligayer, H.1
Boyd, D.D.2
Heiss, M.M.3
-
133
-
-
36248973171
-
The role of Src in prostate cancer
-
Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007, 18(11):1765-1773.
-
(2007)
Ann Oncol
, vol.18
, Issue.11
, pp. 1765-1773
-
-
Fizazi, K.1
-
134
-
-
0034190312
-
Regulation by IGF-I and TGF-beta1 of Swarm-rat chondrosarcoma chondrocytes
-
Matsumura T., Whelan M.C., Li X.Q., et al. Regulation by IGF-I and TGF-beta1 of Swarm-rat chondrosarcoma chondrocytes. JOrthop Res 2000, 18(3):351-355.
-
(2000)
JOrthop Res
, vol.18
, Issue.3
, pp. 351-355
-
-
Matsumura, T.1
Whelan, M.C.2
Li, X.Q.3
-
135
-
-
80053152289
-
IGF-I enhances alpha5beta1 integrin expression and cell motility in human chondrosarcoma cells
-
Wu C.M., Li T.M., Hsu S.F., et al. IGF-I enhances alpha5beta1 integrin expression and cell motility in human chondrosarcoma cells. JCell Physiol 2011, 226(12):3270-3277.
-
(2011)
JCell Physiol
, vol.226
, Issue.12
, pp. 3270-3277
-
-
Wu, C.M.1
Li, T.M.2
Hsu, S.F.3
-
136
-
-
67651152911
-
Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors
-
Ho L., Stojanovski A., Whetstone H., et al. Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 2009, 16(2):126-136.
-
(2009)
Cancer Cell
, vol.16
, Issue.2
, pp. 126-136
-
-
Ho, L.1
Stojanovski, A.2
Whetstone, H.3
-
137
-
-
0033057553
-
Clear cell chondrosarcoma: a pathological and immunohistochemical study
-
Masui F., Ushigome S., Fujii K. Clear cell chondrosarcoma: a pathological and immunohistochemical study. Histopathology 1999, 34(5):447-452.
-
(1999)
Histopathology
, vol.34
, Issue.5
, pp. 447-452
-
-
Masui, F.1
Ushigome, S.2
Fujii, K.3
-
138
-
-
0035190898
-
Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome
-
Sulzbacher I., Birner P., Trieb K., et al. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol 2001, 25(12):1520-1527.
-
(2001)
Am J Surg Pathol
, vol.25
, Issue.12
, pp. 1520-1527
-
-
Sulzbacher, I.1
Birner, P.2
Trieb, K.3
-
139
-
-
84860338071
-
Dedifferentiated peripheral chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of four cases
-
Franchi A., Baroni G., Sardi I., et al. Dedifferentiated peripheral chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of four cases. Virchows Arch 2012, 460(3):335-342.
-
(2012)
Virchows Arch
, vol.460
, Issue.3
, pp. 335-342
-
-
Franchi, A.1
Baroni, G.2
Sardi, I.3
-
140
-
-
79551701930
-
Aphase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or -beta: an Italian Sarcoma Group study
-
Grignani G., Palmerini E., Stacchiotti S., et al. Aphase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or -beta: an Italian Sarcoma Group study. Cancer 2011, 117(4):826-831.
-
(2011)
Cancer
, vol.117
, Issue.4
, pp. 826-831
-
-
Grignani, G.1
Palmerini, E.2
Stacchiotti, S.3
-
141
-
-
84856253146
-
Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report
-
Dallas J., Imanirad I., Rajani R., et al. Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report. JMed Case Rep 2012, 6:41.
-
(2012)
JMed Case Rep
, vol.6
, pp. 41
-
-
Dallas, J.1
Imanirad, I.2
Rajani, R.3
-
142
-
-
71749111001
-
Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb)
-
Jennes I., Pedrini E., Zuntini M., et al. Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat 2009, 30(12):1620-1627.
-
(2009)
Hum Mutat
, vol.30
, Issue.12
, pp. 1620-1627
-
-
Jennes, I.1
Pedrini, E.2
Zuntini, M.3
-
143
-
-
0033924650
-
EXT genes are differentially expressed in bone and cartilage during mouse embryogenesis
-
Stickens D., Brown D., Evans G.A. EXT genes are differentially expressed in bone and cartilage during mouse embryogenesis. Dev Dyn 2000, 218(3):452-464.
-
(2000)
Dev Dyn
, vol.218
, Issue.3
, pp. 452-464
-
-
Stickens, D.1
Brown, D.2
Evans, G.A.3
-
144
-
-
84857789522
-
Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT
-
de Andrea C.E., Reijnders C.M., Kroon H.M., et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene 2012, 31(9):1095-1104.
-
(2012)
Oncogene
, vol.31
, Issue.9
, pp. 1095-1104
-
-
de Andrea, C.E.1
Reijnders, C.M.2
Kroon, H.M.3
-
145
-
-
0032573058
-
The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation
-
Chung U.I., Lanske B., Lee K., et al. The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc Natl Acad Sci USA 1998, 95:13030-13035.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 13030-13035
-
-
Chung, U.I.1
Lanske, B.2
Lee, K.3
-
146
-
-
0035135642
-
Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development
-
Chung U.I., Schipani E., McMahon A.P., et al. Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. JClin Invest 2001, 107(3):295-304.
-
(2001)
JClin Invest
, vol.107
, Issue.3
, pp. 295-304
-
-
Chung, U.I.1
Schipani, E.2
McMahon, A.P.3
-
147
-
-
62549142642
-
Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma
-
Schrage Y.M., Hameetman L., Szuhai K., et al. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. Am J Pathol 2009, 174(3):979-988.
-
(2009)
Am J Pathol
, vol.174
, Issue.3
, pp. 979-988
-
-
Schrage, Y.M.1
Hameetman, L.2
Szuhai, K.3
-
148
-
-
30344434306
-
Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation
-
Tiet T.D., Hopyan S., Nadesan P., et al. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 2006, 168(1):321-330.
-
(2006)
Am J Pathol
, vol.168
, Issue.1
, pp. 321-330
-
-
Tiet, T.D.1
Hopyan, S.2
Nadesan, P.3
-
149
-
-
38449123707
-
Indian hedgehog signaling pathway differences between swarm rat chondrosarcoma and native rat chondrocytes
-
Oji G.S., Gomez P., Kurriger G., et al. Indian hedgehog signaling pathway differences between swarm rat chondrosarcoma and native rat chondrocytes. Iowa Orthop J 2007, 27:9-16.
-
(2007)
Iowa Orthop J
, vol.27
, pp. 9-16
-
-
Oji, G.S.1
Gomez, P.2
Kurriger, G.3
-
150
-
-
67650723106
-
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)
-
Tremblay M.R., Lescarbeau A., Grogan M.J., et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). JMed Chem 2009, 52(14):4400-4418.
-
(2009)
JMed Chem
, vol.52
, Issue.14
, pp. 4400-4418
-
-
Tremblay, M.R.1
Lescarbeau, A.2
Grogan, M.J.3
-
151
-
-
77954150125
-
Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma
-
de Andrea C.E., Wiweger M., Prins F., et al. Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma. Lab Invest 2010, 90(7):1091-1101.
-
(2010)
Lab Invest
, vol.90
, Issue.7
, pp. 1091-1101
-
-
de Andrea, C.E.1
Wiweger, M.2
Prins, F.3
-
152
-
-
84888355058
-
Primary cilia attenuate hedgehog signalling in neoplastic chondrocytes
-
[Epub ahead of print]
-
Ho L., Ali S.A., Al-Jazrawe M., et al. Primary cilia attenuate hedgehog signalling in neoplastic chondrocytes. Oncogene 2012, [Epub ahead of print].
-
(2012)
Oncogene
-
-
Ho, L.1
Ali, S.A.2
Al-Jazrawe, M.3
-
153
-
-
14944367973
-
Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas
-
Rozeman L.B., Hameetman L., Cleton-Jansen A.M., et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. JPathol 2005, 205(4):476-482.
-
(2005)
JPathol
, vol.205
, Issue.4
, pp. 476-482
-
-
Rozeman, L.B.1
Hameetman, L.2
Cleton-Jansen, A.M.3
-
154
-
-
13444292084
-
Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21
-
Shen Z.N., Nishida K., Doi H., et al. Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. Biochem Biophys Res Commun 2005, 328(2):375-382.
-
(2005)
Biochem Biophys Res Commun
, vol.328
, Issue.2
, pp. 375-382
-
-
Shen, Z.N.1
Nishida, K.2
Doi, H.3
-
155
-
-
66949166405
-
SiRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells
-
Kim D.W., Kim K.O., Shin M.J., et al. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer 2009, 8:28.
-
(2009)
Mol Cancer
, vol.8
, pp. 28
-
-
Kim, D.W.1
Kim, K.O.2
Shin, M.J.3
-
156
-
-
34249686133
-
Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells
-
Kim D.W., Seo S.W., Cho S.K., et al. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. JOrthop Res 2007, 25(6):820-828.
-
(2007)
JOrthop Res
, vol.25
, Issue.6
, pp. 820-828
-
-
Kim, D.W.1
Seo, S.W.2
Cho, S.K.3
-
157
-
-
79953254209
-
The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells invitro
-
Lechler P., Renkawitz T., Campean V., et al. The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells invitro. BMC Cancer 2011, 11:120.
-
(2011)
BMC Cancer
, vol.11
, pp. 120
-
-
Lechler, P.1
Renkawitz, T.2
Campean, V.3
-
158
-
-
47349118371
-
Tissue microarrays analysis in chondrosarcomas: light microscopy, immunohistochemistry and xenograft study
-
Machado I., Giner F., Mayordomo E., et al. Tissue microarrays analysis in chondrosarcomas: light microscopy, immunohistochemistry and xenograft study. Diagn Pathol 2008, 3(Suppl 1):S25.
-
(2008)
Diagn Pathol
, vol.3
, Issue.SUPPL 1
-
-
Machado, I.1
Giner, F.2
Mayordomo, E.3
-
159
-
-
84869206991
-
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) Agonist
-
Subbiah V., Brown R.E., Buryanek J., et al. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) Agonist. Mol Cancer Ther 2012, 11(11):2541-2546.
-
(2012)
Mol Cancer Ther
, vol.11
, Issue.11
, pp. 2541-2546
-
-
Subbiah, V.1
Brown, R.E.2
Buryanek, J.3
-
160
-
-
47949092316
-
Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
-
Camidge D.R. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin Biol Ther 2008, 8(8):1167-1176.
-
(2008)
Expert Opin Biol Ther
, vol.8
, Issue.8
, pp. 1167-1176
-
-
Camidge, D.R.1
-
161
-
-
79961117100
-
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments
-
Witkiewicz A.K., Knudsen K.E., Dicker A.P., et al. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 2011, 10(15):2497-2503.
-
(2011)
Cell Cycle
, vol.10
, Issue.15
, pp. 2497-2503
-
-
Witkiewicz, A.K.1
Knudsen, K.E.2
Dicker, A.P.3
-
162
-
-
84885172232
-
Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation
-
[Epub ahead of print]
-
Landman A.S., Danielian P.S., Lees J.A. Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation. Oncogene 2012, [Epub ahead of print].
-
(2012)
Oncogene
-
-
Landman, A.S.1
Danielian, P.S.2
Lees, J.A.3
-
163
-
-
72849137623
-
Central chondrosarcoma progression is associated with pRb pathway alterations; CDK4 downregulation and p16 overexpression inhibit cell growth invitro
-
Schrage Y.M., Lam S., Jochemsen A.G., et al. Central chondrosarcoma progression is associated with pRb pathway alterations; CDK4 downregulation and p16 overexpression inhibit cell growth invitro. JCell Mol Med 2008, 13(9A):2843-2852.
-
(2008)
JCell Mol Med
, vol.13
, Issue.9 A
, pp. 2843-2852
-
-
Schrage, Y.M.1
Lam, S.2
Jochemsen, A.G.3
-
164
-
-
65249118270
-
Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors
-
Hallor K.H., Staaf J., Bovée J.V., et al. Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res 2009, 15(8):2685-2694.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.8
, pp. 2685-2694
-
-
Hallor, K.H.1
Staaf, J.2
Bovée, J.V.3
-
165
-
-
1542345406
-
Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression
-
van Beerendonk H.M., Rozeman L.B., Taminiau A.H., et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. JPathol 2004, 202(3):359-366.
-
(2004)
JPathol
, vol.202
, Issue.3
, pp. 359-366
-
-
van Beerendonk, H.M.1
Rozeman, L.B.2
Taminiau, A.H.3
-
166
-
-
0035071674
-
Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma
-
Asp J., Inerot S., Block J.A., et al. Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma. JOrthop Res 2001, 19(1):149-154.
-
(2001)
JOrthop Res
, vol.19
, Issue.1
, pp. 149-154
-
-
Asp, J.1
Inerot, S.2
Block, J.A.3
-
167
-
-
84869399137
-
Homozygous deletions of cadherin genes in chondrosarcoma-an array comparative genomic hybridization study
-
Niini T., Scheinin I., Lahti L., et al. Homozygous deletions of cadherin genes in chondrosarcoma-an array comparative genomic hybridization study. Cancer Genet 2012, 205(11):588-593.
-
(2012)
Cancer Genet
, vol.205
, Issue.11
, pp. 588-593
-
-
Niini, T.1
Scheinin, I.2
Lahti, L.3
-
168
-
-
0043065484
-
Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma
-
Ropke M., Boltze C., Neumann H.W., et al. Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. Pathol Res Pract 2003, 199(6):437-444.
-
(2003)
Pathol Res Pract
, vol.199
, Issue.6
, pp. 437-444
-
-
Ropke, M.1
Boltze, C.2
Neumann, H.W.3
-
169
-
-
79952734485
-
Aphase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
-
Pacey S., Wilson R.H., Walton M., et al. Aphase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011, 17(6):1561-1570.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.6
, pp. 1561-1570
-
-
Pacey, S.1
Wilson, R.H.2
Walton, M.3
-
170
-
-
0030593509
-
Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas
-
Jagasia A.A., Block J.A., Qureshi A., et al. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett 1996, 105:91-103.
-
(1996)
Cancer Lett
, vol.105
, pp. 91-103
-
-
Jagasia, A.A.1
Block, J.A.2
Qureshi, A.3
-
171
-
-
0030593473
-
Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma
-
Jagasia A.A., Block J.A., Diaz M.O., et al. Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma. Cancer Lett 1996, 105:77-90.
-
(1996)
Cancer Lett
, vol.105
, pp. 77-90
-
-
Jagasia, A.A.1
Block, J.A.2
Diaz, M.O.3
-
172
-
-
33646043791
-
Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas
-
Chow W.A., Bedell V., Gaytan P., et al. Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas. Cancer Genet Cytogenet 2006, 166(2):95-100.
-
(2006)
Cancer Genet Cytogenet
, vol.166
, Issue.2
, pp. 95-100
-
-
Chow, W.A.1
Bedell, V.2
Gaytan, P.3
-
173
-
-
79953319582
-
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies
-
Bertino J.R., Waud W.R., Parker W.B., et al. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biol Ther 2011, 11(7):627-632.
-
(2011)
Cancer Biol Ther
, vol.11
, Issue.7
, pp. 627-632
-
-
Bertino, J.R.1
Waud, W.R.2
Parker, W.B.3
-
174
-
-
28144449722
-
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma
-
Cleton-Jansen A.M., van Beerendonk H.M., Baelde H.J., et al. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005, 11(22):8028-8035.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.22
, pp. 8028-8035
-
-
Cleton-Jansen, A.M.1
van Beerendonk, H.M.2
Baelde, H.J.3
-
175
-
-
37549046081
-
Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas
-
Grifone T.J., Haupt H.M., Podolski V., et al. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas. Int J Surg Pathol 2008, 16(1):31-37.
-
(2008)
Int J Surg Pathol
, vol.16
, Issue.1
, pp. 31-37
-
-
Grifone, T.J.1
Haupt, H.M.2
Podolski, V.3
-
176
-
-
82255189352
-
Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both invitro and invivo
-
Meijer D., Gelderblom H., Karperien M., et al. Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both invitro and invivo. Clin Sarcoma Res 2011, 1(1):5.
-
(2011)
Clin Sarcoma Res
, vol.1
, Issue.1
, pp. 5
-
-
Meijer, D.1
Gelderblom, H.2
Karperien, M.3
-
177
-
-
34547751799
-
2-Methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells
-
Fong Y.C., Yang W.H., Hsu S.F., et al. 2-Methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. JOrthop Res 2007, 25(8):1106-1114.
-
(2007)
JOrthop Res
, vol.25
, Issue.8
, pp. 1106-1114
-
-
Fong, Y.C.1
Yang, W.H.2
Hsu, S.F.3
-
178
-
-
79951727359
-
Cyclooxygenase-2 in oncogenesis
-
Rizzo M.T. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011, 412(9-10):671-687.
-
(2011)
Clin Chim Acta
, vol.412
, Issue.9-10
, pp. 671-687
-
-
Rizzo, M.T.1
-
179
-
-
3042638497
-
Cyclooxygenase-2 expression in chondrosarcoma
-
Sutton K.M., Wright M., Fondren G., et al. Cyclooxygenase-2 expression in chondrosarcoma. Oncology 2004, 66(4):275-280.
-
(2004)
Oncology
, vol.66
, Issue.4
, pp. 275-280
-
-
Sutton, K.M.1
Wright, M.2
Fondren, G.3
-
180
-
-
75149147598
-
COX-2 expression in chondrosarcoma: a role for celecoxib treatment?
-
Schrage Y.M., Machado I., Meijer D., et al. COX-2 expression in chondrosarcoma: a role for celecoxib treatment?. Eur J Cancer 2010, 46:616-624.
-
(2010)
Eur J Cancer
, vol.46
, pp. 616-624
-
-
Schrage, Y.M.1
Machado, I.2
Meijer, D.3
-
181
-
-
33645121064
-
Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas
-
Endo M., Matsumura T., Yamaguchi T., et al. Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol 2006, 37(4):471-476.
-
(2006)
Hum Pathol
, vol.37
, Issue.4
, pp. 471-476
-
-
Endo, M.1
Matsumura, T.2
Yamaguchi, T.3
-
182
-
-
79551703145
-
Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors
-
Bagatell R., Herzog C.E., Trippett T.M., et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011, 17(3):611-619.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.3
, pp. 611-619
-
-
Bagatell, R.1
Herzog, C.E.2
Trippett, T.M.3
-
183
-
-
24944519394
-
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study
-
Daw N.C., Furman W.L., Stewart C.F., et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. JClin Oncol 2005, 23(25):6172-6180.
-
(2005)
JClin Oncol
, vol.23
, Issue.25
, pp. 6172-6180
-
-
Daw, N.C.1
Furman, W.L.2
Stewart, C.F.3
-
184
-
-
38649105118
-
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study
-
Glade Bender J.L., Adamson P.C., Reid J.M., et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. JClin Oncol 2008, 26(3):399-405.
-
(2008)
JClin Oncol
, vol.26
, Issue.3
, pp. 399-405
-
-
Glade Bender, J.L.1
Adamson, P.C.2
Reid, J.M.3
-
185
-
-
77349095970
-
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
-
van C.H., Voest E.E., Punt C.J., et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer 2010, 46(5):901-911.
-
(2010)
Eur J Cancer
, vol.46
, Issue.5
, pp. 901-911
-
-
van, C.H.1
Voest, E.E.2
Punt, C.J.3
-
186
-
-
0033952086
-
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study
-
Merimsky O., Meller I., Flusser G., et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000, 45(2):177-181.
-
(2000)
Cancer Chemother Pharmacol
, vol.45
, Issue.2
, pp. 177-181
-
-
Merimsky, O.1
Meller, I.2
Flusser, G.3
-
187
-
-
84871104475
-
Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study
-
Warwick A.B., Malempati S., Krailo M., et al. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2013, 60(2):237-241.
-
(2013)
Pediatr Blood Cancer
, vol.60
, Issue.2
, pp. 237-241
-
-
Warwick, A.B.1
Malempati, S.2
Krailo, M.3
-
188
-
-
0035281734
-
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity
-
Delaloge S., Yovine A., Taamma A., et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. JClin Oncol 2001, 19(5):1248-1255.
-
(2001)
JClin Oncol
, vol.19
, Issue.5
, pp. 1248-1255
-
-
Delaloge, S.1
Yovine, A.2
Taamma, A.3
-
189
-
-
19944426087
-
Aphase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study
-
Lau L., Supko J.G., Blaney S., et al. Aphase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res 2005, 11(2 Pt 1):672-677.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.2 PART 1
, pp. 672-677
-
-
Lau, L.1
Supko, J.G.2
Blaney, S.3
-
190
-
-
0043073206
-
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
-
Laverdiere C., Kolb E.A., Supko J.G., et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003, 98(4):832-840.
-
(2003)
Cancer
, vol.98
, Issue.4
, pp. 832-840
-
-
Laverdiere, C.1
Kolb, E.A.2
Supko, J.G.3
-
191
-
-
0029766561
-
Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants
-
Patel S.R., Papadopoulos N.E., Plager C., et al. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 1996, 78(4):741-744.
-
(1996)
Cancer
, vol.78
, Issue.4
, pp. 741-744
-
-
Patel, S.R.1
Papadopoulos, N.E.2
Plager, C.3
-
192
-
-
10844236347
-
Aphase II study of docetaxel for the treatment of recurrent osteosarcoma
-
McTiernan A., Whelan J.S. Aphase II study of docetaxel for the treatment of recurrent osteosarcoma. Sarcoma 2004, 8(2-3):71-76.
-
(2004)
Sarcoma
, vol.8
, Issue.2-3
, pp. 71-76
-
-
McTiernan, A.1
Whelan, J.S.2
-
193
-
-
33646045624
-
Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group
-
Zwerdling T., Krailo M., Monteleone P., et al. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer 2006, 106(8):1821-1828.
-
(2006)
Cancer
, vol.106
, Issue.8
, pp. 1821-1828
-
-
Zwerdling, T.1
Krailo, M.2
Monteleone, P.3
-
194
-
-
74549224326
-
Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the Children's Oncology Group
-
Jacobs S., Fox E., Krailo M., et al. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the Children's Oncology Group. Clin Cancer Res 2010, 16(2):750-754.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.2
, pp. 750-754
-
-
Jacobs, S.1
Fox, E.2
Krailo, M.3
-
195
-
-
38649140450
-
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
-
Mita M.M., Mita A.C., Chu Q.S., et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. JClin Oncol 2008, 26(3):361-367.
-
(2008)
JClin Oncol
, vol.26
, Issue.3
, pp. 361-367
-
-
Mita, M.M.1
Mita, A.C.2
Chu, Q.S.3
-
196
-
-
84855556875
-
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
-
Chawla S.P., Staddon A.P., Baker L.H., et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. JClin Oncol 2012, 30(1):78-84.
-
(2012)
JClin Oncol
, vol.30
, Issue.1
, pp. 78-84
-
-
Chawla, S.P.1
Staddon, A.P.2
Baker, L.H.3
-
197
-
-
84861335102
-
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
-
Schuetze S.M., Zhao L., Chugh R., et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer 2012, 48(9):1347-1353.
-
(2012)
Eur J Cancer
, vol.48
, Issue.9
, pp. 1347-1353
-
-
Schuetze, S.M.1
Zhao, L.2
Chugh, R.3
-
198
-
-
0028928375
-
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma
-
Kleinerman E.S., Gano J.B., Johnston D.A., et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995, 18(2):93-99.
-
(1995)
Am J Clin Oncol
, vol.18
, Issue.2
, pp. 93-99
-
-
Kleinerman, E.S.1
Gano, J.B.2
Johnston, D.A.3
-
199
-
-
70449369314
-
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group
-
Chou A.J., Kleinerman E.S., Krailo M.D., et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009, 115(22):5339-5348.
-
(2009)
Cancer
, vol.115
, Issue.22
, pp. 5339-5348
-
-
Chou, A.J.1
Kleinerman, E.S.2
Krailo, M.D.3
-
200
-
-
84885946639
-
Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
-
Stacchiotti S., Dagrada G.P., Morosi C., et al. Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res 2012, 2(1):22.
-
(2012)
Clin Sarcoma Res
, vol.2
, Issue.1
, pp. 22
-
-
Stacchiotti, S.1
Dagrada, G.P.2
Morosi, C.3
-
201
-
-
77956414973
-
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer
-
Herbst R.S., Eckhardt S.G., Kurzrock R., et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. JClin Oncol 2010, 28(17):2839-2846.
-
(2010)
JClin Oncol
, vol.28
, Issue.17
, pp. 2839-2846
-
-
Herbst, R.S.1
Eckhardt, S.G.2
Kurzrock, R.3
|